LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Utilization of glucocorticoids among White and Black patients with systemic lupus erythematosus: Observations from the enrollment visit of a prospective registry.

    Sullivan, James K / Littlejohn, Emily A

    Lupus

    2021  Volume 30, Issue 14, Page(s) 2298–2303

    Abstract: Background: Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated with worse health outcomes among patients with SLE. We sought to ...

    Abstract Background: Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated with worse health outcomes among patients with SLE. We sought to quantify chronic glucocorticoid use among Black and White patients with SLE within a prospective registry.
    Methods: Using enrollment data from a registry at a large academic institution, we compared glucocorticoid use among Black and White patients with SLE. Multivariable logistic regression of race and glucocorticoid use was performed, adjusting for covariates exhibiting a bivariate association with glucocorticoids at significance level
    Results: 114 White participants (mean age 45; standard deviation (SD) 15) and 59 Black participants (mean age 42; SD 14) were analyzed. White participants had mean SLEDAI-2K score of 3.7 (SD 5.2). Black participants had mean SLEDAI-2K scores of 6.3 (SD 6.0). Among Black participants, 43 (72%) utilized glucocorticoids compared to White participants 39 (34%) (unadjusted odds ratio (OR) 5.17; 95% confidence interval (CI) 2.59-10.33). We did not observe differences between unadjusted hydroxychloroquine (OR 0.69; 95% CI 0.28-1.65) or conventional disease-modifying anti-rheumatic drug (cDMARD) (OR 1.07; 95% CI 0.57-2.01) utilization among Black and White participants. SLEDAI-2K, disability, recent hospitalization, and past or present hydroxychloroquine or cDMARD use were included in a logistic regression model. Adjusting for covariates, Black participants were more likely to be on glucocorticoids (adjusted OR 5.69; 95% CI 2.17-14.96);
    Conclusion: Adjusting for disease activity and other medications, Black patients had more exposure to chronic glucocorticoids than White patients in the Cleveland Clinic SLE registry. These patients may face increased glucocorticoid-related morbidity, which could contribute significantly to long-term health outcomes and utilization of health care resources. Future research in larger, more diverse registries should be conducted to further characterize patterns of glucocorticoid use.
    MeSH term(s) Adult ; Antirheumatic Agents/therapeutic use ; Glucocorticoids/therapeutic use ; Humans ; Hydroxychloroquine/therapeutic use ; Lupus Erythematosus, Systemic/drug therapy ; Middle Aged ; Registries ; Severity of Illness Index
    Chemical Substances Antirheumatic Agents ; Glucocorticoids ; Hydroxychloroquine (4QWG6N8QKH)
    Language English
    Publishing date 2021-11-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 1154407-7
    ISSN 1477-0962 ; 0961-2033
    ISSN (online) 1477-0962
    ISSN 0961-2033
    DOI 10.1177/09612033211055817
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Early Diagnosis and Treatment of Rheumatoid Arthritis.

    Littlejohn, Emily A / Monrad, Seetha U

    Primary care

    2018  Volume 45, Issue 2, Page(s) 237–255

    Abstract: Rheumatoid arthritis is the most common inflammatory arthritis, and a significant cause of morbidity and mortality. Primary care providers should be able to distinguish the clinical presentation of rheumatoid arthritis from osteoarthritis, because the ... ...

    Abstract Rheumatoid arthritis is the most common inflammatory arthritis, and a significant cause of morbidity and mortality. Primary care providers should be able to distinguish the clinical presentation of rheumatoid arthritis from osteoarthritis, because the treatment and outcomes differ greatly between these 2 common forms of arthritis. This article provides a current overview of our understanding of rheumatoid arthritis, with an emphasis on early diagnosis and approaches to treatment.
    MeSH term(s) Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/drug therapy ; Diagnosis, Differential ; Disease Progression ; Early Diagnosis ; Humans ; Prognosis
    Chemical Substances Anti-Inflammatory Agents, Non-Steroidal ; Antirheumatic Agents
    Language English
    Publishing date 2018-04-17
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604005-6
    ISSN 1558-299X ; 0095-4543
    ISSN (online) 1558-299X
    ISSN 0095-4543
    DOI 10.1016/j.pop.2018.02.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Corrigendum to "Pregnancy and autoimmune connective tissue diseaes" [Best Practice & Research Clinical Rheumatology 30 (2016) 63-80].

    Marder, Wendy / Littlejohn, Emily A / Somers, Emily C

    Best practice & research. Clinical rheumatology

    2020  Volume 34, Issue 6, Page(s) 101490

    Language English
    Publishing date 2020-04-02
    Publishing country Netherlands
    Document type Published Erratum
    ZDB-ID 2052323-3
    ISSN 1532-1770 ; 1521-6942
    ISSN (online) 1532-1770
    ISSN 1521-6942
    DOI 10.1016/j.berh.2020.101490
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Pregnancy and autoimmune connective tissue diseases.

    Marder, Wendy / Littlejohn, Emily A / Somers, Emily C

    Best practice & research. Clinical rheumatology

    2016  Volume 30, Issue 1, Page(s) 63–80

    Abstract: Autoimmune connective tissue diseases predominantly affect women and often occur during the reproductive years. Thus, specialized issues in pregnancy planning and management are commonly encountered in this patient population. This chapter provides a ... ...

    Abstract Autoimmune connective tissue diseases predominantly affect women and often occur during the reproductive years. Thus, specialized issues in pregnancy planning and management are commonly encountered in this patient population. This chapter provides a current overview of pregnancy as a risk factor for onset of autoimmune disease, considerations related to the course of pregnancy in several autoimmune connective tissue diseases, and disease management and medication issues before pregnancy, during pregnancy, and in the postpartum period. A major theme that has emerged across these inflammatory diseases is that active maternal disease during pregnancy is associated with adverse pregnancy outcomes, and that maternal and fetal health can be optimized when conception is planned during times of inactive disease and through maintaining treatment regimens compatible with pregnancy.
    MeSH term(s) Autoimmune Diseases/immunology ; Connective Tissue Diseases/complications ; Female ; Humans ; Pregnancy ; Pregnancy Complications/immunology ; Pregnancy Outcome ; Risk Factors
    Language English
    Publishing date 2016-06-25
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2052323-3
    ISSN 1532-1770 ; 1521-6942
    ISSN (online) 1532-1770
    ISSN 1521-6942
    DOI 10.1016/j.berh.2016.05.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top